Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | I-O in Gastric/GEJ cancer

Kohei Shitara • 28 Sep 2019
ESMO 2019
Gastrointestinal Cancer Nivolumab Pembrolizumab

Kohei Shitara, MD, National Cancer Center Hospital, Kashiwa, Japan, discussed his opinion on the future of immuno-oncology in gastric and gastroesophageal junction cancer at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Kohei Shitara

3:34
FLOW + SPOTLIGHT: addressing nausea + vomiting in gastric cancer treatment with 1L zolbetuximab
Kohei Shitara • 19 Jan 2024
2:26
NIVO + chemo vs chemo as 1L treatment for advanced GC/GEJC/EAC: 4 year yr follow-up of CheckMate 649
Kohei Shitara • 19 Jan 2024
2:59
The future of gastric cancer treatment beyond ESMO 2023
Kohei Shitara • 21 Oct 2023
4:14
KEYNOTE-585: perioperative pembrolizumab in stomach cancers
Kohei Shitara • 21 Oct 2023

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals